ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dental Pain
Conditions
Dental Pain
Trial Timeline
Nov 11, 2007 → Feb 11, 2008
NCT ID
NCT00542035About ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral is a phase 2 stage product being developed by Pfizer for Dental Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00542035. Target conditions include Dental Pain.
What happened to similar drugs?
1 of 8 similar drugs in Dental Pain were approved
Approved (1) Terminated (0) Active (7)
🔄Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
🔄Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
🔄acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3
🔄Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00542035 | Phase 2 | Completed |
Competing Products
20 competing products in Dental Pain